School of Chemistry, University of Southampton, Southampton SO17 1BJ, U.K.
National University of Ireland, University Road, Galway H91 TK33, Ireland.
J Med Chem. 2022 May 26;65(10):7246-7261. doi: 10.1021/acs.jmedchem.2c00228. Epub 2022 May 17.
The canonical Wingless-related integration site signaling pathway plays a critical role in human physiology, and its dysregulation can lead to an array of diseases. β-Catenin is a multifunctional protein within this pathway and an attractive yet challenging therapeutic target, most notably in oncology. This has stimulated the search for potent small-molecule inhibitors binding directly to the β-catenin surface to inhibit its protein-protein interactions and downstream signaling. Here, we provide an account of the claimed (and some putative) small-molecule ligands of β-catenin from the literature. Through in silico analysis, we show that most of these molecules contain promiscuous chemical substructures notorious for interfering with screening assays. Finally, and in line with this analysis, we demonstrate using orthogonal biophysical techniques that none of the examined small molecules bind at the surface of β-catenin. While shedding doubts on their reported mode of action, this study also reaffirms β-catenin as a prominent target in drug discovery.
经典的 Wingless 相关整合位点信号通路在人体生理学中发挥着关键作用,其失调可能导致多种疾病。β-连环蛋白是该通路中的一种多功能蛋白,是一个有吸引力但具有挑战性的治疗靶点,尤其是在肿瘤学中。这激发了人们对直接与β-连环蛋白表面结合的有效小分子抑制剂的寻找,以抑制其蛋白-蛋白相互作用和下游信号传导。在这里,我们提供了文献中声称的(和一些推测的)β-连环蛋白小分子配体的说明。通过计算机分析,我们表明,这些分子中的大多数都含有混杂的化学亚结构,这些亚结构因干扰筛选试验而臭名昭著。最后,根据这项分析,我们使用正交生物物理技术证明,没有一种被检查的小分子能与β-连环蛋白的表面结合。虽然这对它们报告的作用模式提出了质疑,但这项研究也再次证实了β-连环蛋白是药物发现中的一个重要靶点。